Fresenius Kabi launches generic Firazyr

Fresenius Kabi is offering icatibant injection to treat acute attacks of hereditary angioedema, or HAE in adults.

The product is the generic of Takeda’s Firazyr. It is supplied as a 3-ml, prefilled, single-use syringe that is self-administered subcutaneously into the abdominal area.

Icatibant injection can be used both in and out of the home after training with a health care professional. It treats acute attacks in adults over the age of 18 with HAE, a rare and potentially life-threatening genetic condition impacting roughly 6,000 Americans.

“For people with HAE, an acute attack can occur anywhere, at any time and can be life-threatening,” said John Ducker, president and CEO of Fresenius Kabi USA. “Fresenius Kabi wants to be a valuable resource for patients and their care teams, which is why we are offering a patient support program for the first time.”

In conjunction with launching its first specialty drug, Fresenius Kabi is launching KabiCare, a comprehensive patient support program. KabiCare can help eligible patients access icatibant injection and remain compliant with their therapy by providing access to live case managers, co-pay assistance, self-injection training and pharmaceutical samples to bridge a patient’s therapy in the event there is a delay in a patient’s coverage.